Compare ATEC & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEC | OLMA |
|---|---|---|
| Founded | 1990 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2006 | 2020 |
| Metric | ATEC | OLMA |
|---|---|---|
| Price | $13.90 | $25.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $22.36 | ★ $41.14 |
| AVG Volume (30 Days) | ★ 4.2M | 1.3M |
| Earning Date | 02-24-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $728,020,000.00 | N/A |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | $16.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.11 | N/A |
| 52 Week Low | $8.81 | $2.86 |
| 52 Week High | $23.29 | $36.26 |
| Indicator | ATEC | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 26.75 | 49.49 |
| Support Level | $13.43 | $24.91 |
| Resistance Level | $15.55 | $27.13 |
| Average True Range (ATR) | 0.70 | 1.67 |
| MACD | -0.15 | -0.11 |
| Stochastic Oscillator | 6.91 | 60.87 |
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.